Log in

BioXcel Therapeutics Stock Forecast, Price & News

-0.06 (-0.13 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $44.59
50-Day Range
MA: $49.66
52-Week Range
Now: $44.59
Volume316,416 shs
Average Volume582,514 shs
Market Capitalization$1.09 billion
P/E RatioN/A
Dividend YieldN/A
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Read More
BioXcel Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BTAI



Sales & Book Value

Annual SalesN/A
Book Value$9.07 per share


Net Income$-32,970,000.00


Market Cap$1.09 billion
Next Earnings Date3/8/2021 (Estimated)
OptionableNot Optionable
-0.06 (-0.13 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BTAI News and Ratings via Email

Sign-up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions

How has BioXcel Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

BioXcel Therapeutics' stock was trading at $29.48 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BTAI stock has increased by 51.3% and is now trading at $44.59.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of BioXcel Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioXcel Therapeutics

What stocks does MarketBeat like better than BioXcel Therapeutics?

Wall Street analysts have given BioXcel Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioXcel Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BioXcel Therapeutics' next earnings date?

BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for BioXcel Therapeutics

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its quarterly earnings results on Tuesday, November, 17th. The company reported ($1.07) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.27.
View BioXcel Therapeutics' earnings history

What price target have analysts set for BTAI?

7 brokerages have issued 1-year price objectives for BioXcel Therapeutics' shares. Their forecasts range from $60.00 to $175.00. On average, they anticipate BioXcel Therapeutics' stock price to reach $101.00 in the next year. This suggests a possible upside of 126.5% from the stock's current price.
View analysts' price targets for BioXcel Therapeutics

Are investors shorting BioXcel Therapeutics?

BioXcel Therapeutics saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 2,830,000 shares, an increase of 22.0% from the October 15th total of 2,320,000 shares. Based on an average daily volume of 545,200 shares, the short-interest ratio is currently 5.2 days. Currently, 22.4% of the company's stock are sold short.
View BioXcel Therapeutics' Short Interest

Who are some of BioXcel Therapeutics' key competitors?

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology Group (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

Who are BioXcel Therapeutics' key executives?

BioXcel Therapeutics' management team includes the following people:
  • Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, Sec. & Director (Age 59, Pay $699.8k)
  • Mr. Richard I. Steinhart MBA, VP & CFO (Age 63, Pay $404k)
  • Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 51, Pay $510.17k)
  • Dr. Frank D. Yocca Ph.D., Chief Scientific Officer (Age 64)
  • Dr. Cedric Burg, VP and Head of Global Clinical Operations & Project Management
  • Dr. David C. Hanley, Head of Global Pharmaceutical Devel. and Operations & VP
  • Dr. Chetan D. Lathia, Sr. VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs
  • Mr. William P. Kane Jr., Exec. VP & Chief Commercial Officer
  • Dr. Reina Benabou M.D., Ph.D., Sr. VP & Chief Devel. Officer
  • Dr. Robert Risinger, VP of Clinical Devel.

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (5.79%), Artemis Investment Management LLP (4.48%), BlackRock Inc. (3.62%), Victory Capital Management Inc. (2.66%), Logos Global Management LP (2.46%) and Massachusetts Financial Services Co. MA (1.30%). Company insiders that own BioXcel Therapeutics stock include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta.
View institutional ownership trends for BioXcel Therapeutics

Which major investors are selling BioXcel Therapeutics stock?

BTAI stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Massachusetts Financial Services Co. MA, HighPoint Advisor Group LLC, Wells Fargo & Company MN, LPL Financial LLC, Virtus ETF Advisers LLC, and AQR Capital Management LLC.
View insider buying and selling activity for BioXcel Therapeutics

Which major investors are buying BioXcel Therapeutics stock?

BTAI stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., State Street Corp, Artemis Investment Management LLP, Sphera Funds Management LTD., Logos Global Management LP, BlackRock Inc., Charles Schwab Investment Management Inc., and J. Goldman & Co LP. Company insiders that have bought BioXcel Therapeutics stock in the last two years include Frank Yocca, Peter Mueller, Richard I Steinhart, and Vimal Mehta.
View insider buying and selling activity for BioXcel Therapeutics

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $44.59.

How big of a company is BioXcel Therapeutics?

BioXcel Therapeutics has a market capitalization of $1.09 billion. The company earns $-32,970,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. BioXcel Therapeutics employs 31 workers across the globe.

What is BioXcel Therapeutics' official website?

The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 475-238-6837 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.